Principal Financial Group Inc. Invests $329,000 in Harrow, Inc. (NASDAQ:HROW)

Principal Financial Group Inc. acquired a new position in shares of Harrow, Inc. (NASDAQ:HROW) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 7,320 shares of the company’s stock, valued at approximately $329,000.

Other hedge funds also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Harrow by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after purchasing an additional 227 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Harrow in the second quarter valued at approximately $33,000. Allspring Global Investments Holdings LLC increased its holdings in shares of Harrow by 2,730.7% in the second quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock valued at $44,000 after purchasing an additional 2,048 shares in the last quarter. Hills Bank & Trust Co acquired a new stake in shares of Harrow in the third quarter valued at approximately $107,000. Finally, Clarus Group Inc. bought a new position in Harrow in the third quarter valued at approximately $225,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Trading Down 2.2 %

HROW opened at $42.90 on Monday. The stock has a market capitalization of $1.53 billion, a P/E ratio of -45.64 and a beta of 0.76. Harrow, Inc. has a 12 month low of $8.72 and a 12 month high of $59.23. The firm’s fifty day simple moving average is $47.88 and its 200 day simple moving average is $33.51. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Lake Street Capital raised their price objective on shares of Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, October 4th. Craig Hallum lifted their price target on shares of Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, October 4th. Finally, B. Riley reissued a “buy” rating and set a $50.00 price target on shares of Harrow in a research report on Thursday, August 29th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.